B
NBIX icon

Braidwell’s Neurocrine Biosciences NBIX Stock Holding History

Braidwell’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$56.7M Sell
336,171
-315,950
-48% -$46.9M 2.1% 13
2026
Q1 		$85.9M Sell
652,121
-99,413
-13% -$13.2M 2.87% 5
2025
Q4 		$107M Sell
751,534
-128,748
-15% -$18.7M 3.41% 5
2025
Q3 		$124M Sell
880,282
-280,143
-24% -$38M 3.67% 6
2025
Q2 		$146M Sell
1,160,425
-31,500
-3% -$3.61M 4.99% 3
2025
Q1 		$132M Buy
1,191,925
+290,135
+32% +$36.8M 4.63% 3
2024
Q4 		$123M Sell
901,790
-15,884
-2% -$1.96M 3.65% 4
2024
Q3 		$106M Buy
917,674
+158,665
+21% +$21.8M 3% 7
2024
Q2 		$104M Buy
759,009
+28,800
+4% +$3.95M 3.28% 5
2024
Q1 		$101M Buy
730,209
+15,000
+2% +$2.05M 3.25% 7
2023
Q4 		$94.2M Sell
715,209
-252,815
-26% -$29.1M 3.46% 6
2023
Q3 		$109M Buy
968,024
+34,662
+4% +$3.65M 3.44% 7
2023
Q2 		$88M Buy
933,362
+166,562
+22% +$16.3M 2.88% 8
2023
Q1 		$77.6M Buy
+766,800
New +$79.8M 2.56% 10

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Braidwell's NBIX Position: Q2 2026 in Review

Braidwell reduced its Neurocrine Biosciences (NBIX) stake by 48% in Q2 2026, selling an estimated $46.9M and leaving 336,171 shares worth $56.7M. The position accounts for 2.1% of the portfolio, ranked #13.

Braidwell first reported a position in NBIX in Q1 2023 and has held it in 14 quarters since. The position peaked at $146M in Q2 2025. 775 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Braidwell held 336,171 shares of Neurocrine Biosciences worth $56.7M as of Q2 2026.
  • Braidwell sold 315,950 Neurocrine Biosciences shares in Q2 2026, an estimated $46.9M.
  • Neurocrine Biosciences made up 2.1% of Braidwell's portfolio in Q2 2026, its #13 holding.
  • Braidwell first reported a position in Neurocrine Biosciences in Q1 2023 and has held it in 14 quarters since.
  • Braidwell's Neurocrine Biosciences position peaked at $146M in Q2 2025.
  • 775 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Braidwell's 13F filing for Q2 2026, filed 14 Aug 2026.